As of 2025-07-11, the Relative Valuation of Arrowhead Pharmaceuticals Inc (ARWR) is (20.30) USD. This relative valuation is based on P/E multiples. With the latest stock price at 18.86 USD, the upside of Arrowhead Pharmaceuticals Inc based on Relative Valuation is -207.6%.
The range of the Relative Valuation is (15.66) - (25.73) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.0x - 24.7x | 19.6x |
| Forward P/E multiples | 13.3x - 25.0x | 19.4x |
| Fair Price | (15.66) - (25.73) | (20.30) |
| Upside | -183.0% - -236.4% | -207.6% |
| Date | P/E |
| 2025-07-10 | -18.09 |
| 2025-07-09 | -18.11 |
| 2025-07-08 | -16.82 |
| 2025-07-07 | -16.15 |
| 2025-07-03 | -16.11 |
| 2025-07-02 | -16.21 |
| 2025-07-01 | -15.43 |
| 2025-06-30 | -15.16 |
| 2025-06-27 | -15.42 |
| 2025-06-26 | -15.41 |
| 2025-06-25 | -15.02 |
| 2025-06-24 | -15.31 |
| 2025-06-23 | -14.88 |
| 2025-06-20 | -14.70 |
| 2025-06-18 | -14.98 |
| 2025-06-17 | -14.87 |
| 2025-06-16 | -15.06 |
| 2025-06-13 | -15.10 |
| 2025-06-12 | -15.56 |
| 2025-06-11 | -16.06 |
| 2025-06-10 | -16.28 |
| 2025-06-09 | -15.89 |
| 2025-06-06 | -16.12 |
| 2025-06-05 | -15.79 |
| 2025-06-04 | -16.06 |
| 2025-06-03 | -15.93 |
| 2025-06-02 | -15.73 |
| 2025-05-30 | -15.41 |
| 2025-05-29 | -16.13 |
| 2025-05-28 | -14.93 |
| 2025-05-27 | -14.74 |
| 2025-05-23 | -14.51 |
| 2025-05-22 | -14.76 |
| 2025-05-21 | -14.69 |
| 2025-05-20 | -15.63 |
| 2025-05-19 | -15.10 |
| 2025-05-16 | -15.07 |
| 2025-05-15 | -14.71 |
| 2025-05-14 | -14.30 |
| 2025-05-13 | -14.66 |
| 2025-05-12 | -13.40 |
| 2025-05-09 | -12.50 |
| 2025-05-08 | -12.71 |
| 2025-05-07 | -12.53 |
| 2025-05-06 | -12.55 |
| 2025-05-05 | -13.41 |
| 2025-05-02 | -13.83 |
| 2025-05-01 | -13.47 |
| 2025-04-30 | -13.32 |
| 2025-04-29 | -12.92 |